Moderate Atopic Dermatitis (Eczema) Eczema Dermatitis Skin disorders Nanoparticles
Conditions
Interventions
This formulation will act as the vehicle (placebo) control, matching the experimental gel in appearance, texture, color and The gel will be applied topically to affected areas twice daily for the dura
Aloe vera gel,Aloe vera Gel Containing Curcumin and Luteolin Nano-Lipid Formulation (Investigational Product),Ruxolitinib Gel
Sponsors
Muhammad Nawaz Sharif University of Agriculture
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Patients with pruritus Visual Analog Scale (VAS) score equal or greater than 3 2. Patients with Body Surface Area (BSA) involvement of 2 to 20 3. Patients with Investigators Static Global Assessment (ISGA) score of 2 to 3 and baseline Eczema 4. Area and Severity Index (EASI) score of 4 to 16 indicating mild-to-moderate disease 5. Patients with a history of atopic dermatitis of at least 6 months duration 6. Willingness to provide written informed consent 7. Participants who agree to discontinue the use of other topical or systemic skin treatments during the study period. 8. Participants who have not participated in a similar clinical investigation within the past four weeks
Exclusion criteria
Exclusion criteria: 1. Female subjects who are pregnant, lactating or planning to become pregnant during the study period. 2. A known history or present condition of allergic response and hypersensitivity to any herbal products. 3. Subjects Having bacterial or fungal acne 4. Subject participating in any other cosmetic or therapeutic trial. 5. Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness. 6. Subject has participated in a clinical study within the last 30 days prior to entering this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema Area and Severity Index (EASI) score 8 weeks Dermatology-trained investigators | — |
Secondary
| Measure | Time frame |
|---|---|
| Pruritus severity assessed using Visual Analog Scale (VAS) 8 weeks VAS recorded by participants using a 10-cm scale,ISGA score improvement 8 weeks Dermatology-trained investigators,Change in Body Surface Area involvement 8 weeks BSA assessed using rule of nines/palm method.,Dermatology Life Quality Index (DLQI). 8 weeks DLQI administered as validated questionnaire,Incidence, severity, and relationship of treatment-emergent adverse events and local skin reactions throughout the study period 8 weeks Dermatology-trained investigators | — |
Countries
Pakistan
Contacts
Public ContactMuhammad Usman
Muhammad Nawaz Sharif University of Agriculture
Outcome results
None listed